Chalfont St Giles, UK - September 22 2011 - GE Healthcare Life Science’s DiPIA 2011, the leading forum on developments and trends in the field of label-free interactions analysis will be held in Boston, Massachusetts, USA on November 12-15, 2011.
Attended by leading scientists from both academia and industry, the conference will address many key challenges facing the industry, such as how label-free binding studies can advance fragment based drug discovery and how label-free detection can provide the insights needed to drive progress in biotherapeutic development.
The conference is comprised of educational and scientific sessions, including key lectures, workshops, and round-table sessions covering the latest advances and new solutions. The scientific sessions highlight three forefront topics:
• Fragment and small molecule screening and characterization
Keynote speaker: Tony Giannetti, Genentech, USA.
The short history of fragment based lead discovery and the impact of the quantitative optical biosensor.
• Biotherapeutic and vaccine discovery and development
Keynote Speaker: Indresh Srivastava, NIH, USA.
Biophysical characterization of vaccines
• Structure-activity relationship
Keynote speaker: David Wilson, Georgia State University, USA.
Biosensor-SPR and ITC applications to nucleic acid Interactions: New approaches and biological applications
Delegates will also have the opportunity to take part in pre-conference tutorials addressing the use of Biacore™, MicroCal™ ITC and MicroCal DSC systems, as well as workshops providing educational and practical information on a range of application and methodology-related topics.
For further information of the schedule and registration details please visit: www.gelifesciences.com/dipia
The event is kindly sponsored by Science, GEN, and Pharma
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com
Media Contacts:
College Hill for GE Healthcare
Dr. Lynne Trowbridge, Tim Watson, Dimithri Wignarajah
T: +44 (0) 20 7866 7861
E: ge-proteins@collegehill.com
